骨髓增殖性肿瘤的克隆结构演化:从驱动突变到复杂的异质性突变与表型格局
本文综述骨髓增殖性肿瘤在造血干细胞水平获得靶向JAK/STAT通路的驱动突变,并常伴随信号传导、表观遗传、mRNA剪接或转录等通路的附加突变;综述近年关于突变序贯获得与选择的速度和机制的新信息,以及单细胞技术对克隆结构和突变诱导细胞修饰的解析,并总结克隆选择机制、克隆结构复杂性对疾病异质性的解释及克隆演化对临床演变的影响。
要点
- 骨髓增殖性肿瘤在造血干细胞水平获得靶向JAK/STAT通路的驱动突变。
- 常伴随靶向细胞内信号传导、表观遗传、mRNA剪接或转录等通路的附加突变。
- 单细胞技术可精确解析克隆结构与突变诱导的细胞修饰。
核心结论
- 综述总结克隆选择机制、克隆结构复杂性对疾病异质性的解释及克隆演化对临床演变的影响。
研究设计与样本
- 综述,总结近年关于骨髓增殖性肿瘤克隆结构演化机制与临床影响的知识。
主要发现
- 骨髓增殖性肿瘤在造血干细胞水平获得靶向JAK/STAT通路的驱动突变,并常伴有靶向细胞内信号传导、表观遗传、mRNA剪接或转录等通路的附加突变。
- 自然病史通常表现为持续时间因疾病亚型而异的慢性期,随后可进入加速期或转化为更具侵袭性的疾病如骨髓纤维化或急性白血病。
- 近期研究揭示了骨髓增殖性肿瘤造血细胞中突变序贯获得与选择的速度和机制的重要新信息。
- 新近可用的技术可在单细胞水平精确解析克隆结构和突变诱导的细胞修饰。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an accelerated phase or transformation towards more aggressive diseases such as myelofibrosis or acute leukemia. Besides, recent studies revealed important new information about the rates and mechanisms of sequential acquisition and selection of mutations in hematopoietic cells of myeloproliferative neoplasms. Better understanding of these events has been made possible in large part with the help of novel techniques that are now available to precisely decipher at the single cell level both the clonal architecture and the mutation-induced cell modifications. In this review, we will summarize the most recent knowledge about the mechanisms leading to clonal selection, how clonal architecture complexity can explain disease heterogeneity, and the impact of clonal evolution on clinical evolution.
引用
- Maslah N, Benajiba L, Giraudier S, et al. Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. Leukemia. 2023. PMID: 37002477. doi:10.1038/s41375-023-01886-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。